Organon & Co Securities Lawsuit Investigation

Shamis & Gentile P.A., one of the nation's premier class action law firms specializing in securities fraud cases, is investigating potential claims against Organon & Co (OGN).

If you purchased or held Organon & Co securities between February 13, 2024 and May 01, 2025, you may be eligible to join this securities investigation and seek compensation for your losses.

About Organon & Co

Organon & Co is a global healthcare company that focuses on women’s health, biosimilars, and established brands. The company operates in more than 140 markets worldwide, offering a portfolio of products that include contraception, fertility treatments, and therapies for cardiovascular and respiratory conditions.

Headquartered in Jersey City, New Jersey, Organon was spun off from Merck & Co. in 2021.

The Allegations

The investigation centers on allegations that Organon & Co misled investors regarding the stability of its dividend and the company’s underlying financial health. Throughout the proposed class period, management repeatedly assured shareholders of robust cash flow and stable dividend payments. However, there was little to no disclosure of increasing leverage and liquidity risks that could threaten these returns.

On May 1, 2025, Organon & Co shocked investors by slashing its quarterly dividend by over 90% and reporting disappointing revenues. This abrupt reversal came without prior warnings or risk disclosures, sharply contradicting earlier statements. The announcement triggered a dramatic stock price decline of nearly 27% in a single day.

This sudden shift in strategy and lack of transparency has prompted securities law investigations and raised serious concerns about whether investors were provided with accurate and complete information during the class period.

Proposed Class Period

The proposed class period for this investigation is February 13, 2024 to May 01, 2025.

The class period is significant because it defines which investors may be eligible to participate in any future class action lawsuit. If you purchased or held Organon & Co securities during this time, your rights could be directly affected by the outcome of this investigation.

Your Rights and Next Steps

As an investor, you have the right to know whether you were misled by Organon & Co’s public statements. This is currently an investigation, not a filed lawsuit. The goal is to determine whether there is sufficient evidence to support a securities class action on behalf of affected investors.

If you purchased or held Organon & Co securities during the proposed class period, you may be eligible to join this investigation. By participating, you help ensure that your interests are represented and that you stay informed about any developments, including the possible filing of a class action lawsuit.

Lawyers are ready to help answer your questions and guide you through the process. There is no cost to join the investigation, and your information will remain confidential.

You May Be Entitled to Compensation

Securities investigations are time-sensitive. If you suffered financial losses as a result of Organon & Co’s alleged misstatements or omissions, you may be entitled to compensation if a class action lawsuit is filed and is successful.

To protect your rights and maximize your potential recovery, complete the below form to join the investigation. Lawyers are ready to help you understand your options and keep you updated as the case progresses.